Arthritis & Rheumatology最新文献

{"title":"Exploring the Potential of Cluster Analysis in Identifying Disease Phenotypes in Calcium Pyrophosphate Deposition: Moving From Intuition to Insight.","authors":"Greta Pellegrino, Laurène Norberciak, Silvia Sirotti, Abhishek Abhishek, Mariano Andrès, Edoardo Cipolletta, Julien Damart, Renaud Desbarbieux, Pilar Diez, Vincent Ducoulombier, Hang-Korng Ea, Emilio Filippucci, Charlotte Jauffret, Augustin Latourte, Jean-Guillaume Letarouilly, Sébastien Ottaviani, Laura Pezzoni, Pascal Richette, Pierre Robinet, Georgios Filippou, Tristan Pascart","doi":"10.1002/art.70345","DOIUrl":"10.1002/art.70345","url":null,"abstract":"<p><strong>Objective: </strong>Calcium pyrophosphate deposition (CPPD) disease is a heterogeneous condition and is frequently misdiagnosed due to the different clinical presentations and variable disease progression. Aim of this study is to identify clinical phenotypes of CPPD disease by integrating real-world data from two data sets.</p><p><strong>Methods: </strong>Data from the COLCHICORT trial and CHRONIC CPPD European observational cohort were analyzed. Multiple correspondence analysis (MCA) was employed to evaluate and visualize the association between modalities of quantitative variables. Hierarchical clustering on principal components were obtained from MCA-identified clusters based on Ward agglomeration method with Euclidean distance. A bivariate analysis between clusters was then performed to characterize the clusters numerically.</p><p><strong>Results: </strong>A total of 134 patients were included in the analysis, resulting in four distinct clusters. Cluster 1 had predominantly monoarticular involvement, frequent recurrent flares, older age at onset, female prevalence, and high C-reactive protein (CRP) levels. Cluster 2 also involved monoarticular cases but with persistent arthritis and onset after 60 years, with about half exhibiting elevated CRP. Cluster 3 included polyarticular cases, featuring persistent arthritis and lower CRP levels, whereas cluster 4 highlighted polyarticular involvement (spine and shoulder included) and primarily recurrent flares.</p><p><strong>Conclusion: </strong>In conclusion, by using for the first time a robust, data-driven methodology based on real-world data, two clusters similar to the EULAR phenotypes \"acute CPP crystal arthritis,\" and \"chronic CPP crystal inflammatory arthritis\" were confirmed, but in addition, two more clusters that do not correspond to any existing EULAR phenotypes were also identified. Due to the characteristics of the cohorts, the osteoarthritis plus CPPD cluster has not been explored.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148987305","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Transcriptomic Profiling in Skeletal Muscle Identifies Associations With Knee Osteoarthritis: the Study of Muscle, Mobility and Aging (SOMMA)","authors":"Daniel S. Evans, Tyler A. Mansfield, Gina M. Many, Tyler J. Sagendorf, Samaneh Farsijani, Bret H. Goodpaster, Lauren M. Sparks, Nancy E. Lane","doi":"10.1002/art.70341","DOIUrl":"https://doi.org/10.1002/art.70341","url":null,"abstract":"Objectives The association between skeletal muscle gene expression and knee osteoarthritis (OA) was examined among older adult participants of the Study of Muscle, Mobility and Aging (SOMMA). Methods Inclusion criteria included knee radiographs and bulk RNA sequencing (RNAseq) in <jats:italic>vastus lateralis</jats:italic> muscle, resulting in 523 participants (56% female). Radiographic knee OA was determined by Kellgren‐Lawrence (KL) grades. Differential gene expression was analyzed using a control group (KL ≤ 1, n = 326) and two nested case groups: (a) KL ≥ 2 (n = 197), (b) KL ≥ 3 (n = 112). Results Compared with controls, there were 27 and 41 genes associated (FDR ≤ 0.05) with KL ≥ 2 and KL ≥ 3, respectively, and 16 genes significantly associated in both contrasts. For 15 of the 16 genes, the association magnitude was larger with more severe OA (KL ≥ 3). Genes associated in both contrasts included brain‐derived neurotrophic factor (BDNF) and interferon regulatory factor‐2 (IRF2). Gene sets enriched in KL ≥ 2 and KL ≥ 3 contrasts included DNA repair and branched chain amino acid (BCAA) catabolism. Conclusions Our results in older adult SOMMA participants indicate that knee OA is associated with genes and pathways expressed in skeletal muscle that are involved in pain sensitization, BCAA catabolism, muscle function preservation, calcium transport and storage, inflammation, and extracellular matrix remodeling. Additional longitudinal studies will be needed to determine how these genes could affect the progression of knee OA. <jats:boxed-text content-type=\"graphic\" position=\"anchor\"> <jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" mimetype=\"image/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic/art70341-toc-0001-m.png\"> <jats:alt-text>image</jats:alt-text> </jats:graphic> </jats:boxed-text>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"2 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Shared and Distinguishing Features of Late‐Onset Rheumatic Diseases Fulfilling Polymyalgia Rheumatica Classification Criteria","authors":"Kerem Abacar, Ala Altaie, Andrew Barr, Sarah L. Mackie, Kulveer Mankia, Dennis McGonagle","doi":"10.1002/art.70339","DOIUrl":"https://doi.org/10.1002/art.70339","url":null,"abstract":"‐","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"382 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rheumatology Informatics System for Effectiveness (RISE) Registry Participation Associated with Significant Gains in Quality Measure Performance: An Interrupted Time Series Analysis","authors":"Gabriela Schmajuk, Jessica Fitzpatrick, Jing Li, Stephen Shiboski, Emma Kersey, Jinoos Yazdany","doi":"10.1002/art.70340","DOIUrl":"https://doi.org/10.1002/art.70340","url":null,"abstract":"Objective To examine the association between participation in a qualified clinical data registry and quality measure performance. Methods We included practices that joined the American College of Rheumatology's Rheumatology Informatics System for Effectiveness (RISE) registry between 2015 – 2021. We calculated annual performance on 4 primary measures and 2 control measures starting 12 months before through 18 months after enrollment. We used an interrupted time‐series (ITS) analysis to assess changes in practice‐level performance before and after RISE enrollment overall and stratified by practices’ baseline performance. Results We included 85 practices caring for 331,975 patients. Overall, performance on all primary measures improved during the study period, although RISE enrollment was associated with a significantly greater improvement rate in 1 of the 4 primary measures (RA functional status assessment (slope difference 0.88 percentage points/month; p=0.006). Practices with baseline lower performance had significantly greater improvements after joining RISE for 3 out of the 4 primary measures compared to high‐performing practices, including RA functional status assessment, TB screening prior to biologic therapy, and osteoporosis screening. Conclusions RISE enrollment was associated with significant improvements in 3 out of 4 rheumatology‐specific quality measures for practices with lower baseline performance. These findings suggest that registry participation may accelerate uptake of best practices and narrow performance gaps across sites. Future work is needed to understand the mechanisms underlying these improvements.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"88 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative Safety of Common Immunosuppressant Therapies in Systemic Lupus Erythematosus: A Target Trial Emulation Study","authors":"Alí Duarte‐García, Marlon J. Sandino‐Bermúdez, Mariana González‐Treviño, Cynthia S. Crowson, Rozalina G. McCoy, Yihong Deng","doi":"10.1002/art.70343","DOIUrl":"https://doi.org/10.1002/art.70343","url":null,"abstract":"Objective Compare infection‐related hospitalization risk among patients with non‐renal SLE initiating commonly used immunosuppressants. Methods We emulated a target trial using Optum Labs Data Warehouse claims to compare the risk of infection‐related hospitalization among patients initiating azathioprine, belimumab, methotrexate, or mycophenolic acid analogues (MPAA) between March 2011 and September 2023. We excluded patients with prior lupus nephritis, solid‐organ or bone marrow transplantation, or rituximab/cyclophosphamide exposure. The primary outcome was time to first infection‐related hospitalization, using intention‐to‐treat (ITT) and per‐protocol (PP) analyses. We applied inverse probability of treatment weighting to account for baseline covariates and fitted marginal structural Cox models incorporating time‐varying monthly glucocorticoid dose during follow‐up. Results Among 6,168 patients, 24‐month cumulative incidence of infection‐related hospitalization was 10% (95%CI 8–12) for azathioprine, 8% (95%CI 5–10) for belimumab, 10% (95%CI 8–11) for methotrexate, and 13% (95%CI 10–15) for MPAA. In ITT analyses, MPAA had higher risk than belimumab (HR 1.55; 95%CI 1.07–2.25) and methotrexate (HR 1.32; 95%CI 1.04–1.68). In PP analyses, azathioprine (HR 2.04; 95%CI 1.01–4.16) and MPAA (HR 2.27; 95%CI 1.11–4.62) had higher risk compared with belimumab. After accounting for time‐varying monthly glucocorticoid dose, between‐treatment differences were no longer significant. Conclusions Initial differences in the infection‐related hospitalization risk were attenuated after accounting for time‐varying glucocorticoid exposure. These findings highlight glucocorticoid exposure as an important factor associated with serious infection risk, while recognizing that post‐baseline glucocorticoid use may reflect both evolving disease activity and a pathway through which therapies influence infection risk. <jats:boxed-text content-type=\"graphic\" position=\"anchor\"> <jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" mimetype=\"image/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic/art70343-toc-0001-m.png\"> <jats:alt-text>image</jats:alt-text> </jats:graphic> </jats:boxed-text>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"15 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148979468","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incidence and Disease Course of Polymyalgia Rheumatica During Two Decades: A Nationwide Study Across Health Care Sectors in Denmark.","authors":"Agnete Overgaard Donskov, Ellen Margrethe Hauge, Annette De Thurah, Mette Nørgaard, Kresten Krarup Keller","doi":"10.1002/art.70337","DOIUrl":"10.1002/art.70337","url":null,"abstract":"<p><strong>Objective: </strong>A new algorithm enables the identification of patients with polymyalgia rheumatica (PMR) across health care sectors in Denmark. We estimated annual incidence rates from 2003 to 2024 and described the disease course, including the occurrence of late-onset giant cell arteritis (GCA) and prednisolone or prednisone (PDN) treatment.</p><p><strong>Methods: </strong>A Danish nationwide, population-based cohort study was conducted using data linked at the individual level. Cases were identified among people ages 50 years or older between January 1, 2003, and November 1, 2024.</p><p><strong>Results: </strong>A total of 51,401 patients were identified, including 24,456 from primary care and 26,945 from secondary care. The age-standardized incidence of PMR was 112 per 100,000 people (95% confidence interval [CI] 110.8-112.8). During the study period, the incidence declined by 53% in primary health care and increased by 30% in secondary health care, resulting in an overall decline of 12%. Among patients with PMR, GCA occurred at a rate of 5.4 (95% CI 5.1-5.7) per 1,000 patient-years, with a median of 68 days (interquartile range 10-602) from PMR diagnosis. Overall, 28% and 22% of patients were still treated with PDN after 5 and 10 years, with a median daily dose of 4.1 and 5.5 mg of PDN, respectively.</p><p><strong>Conclusion: </strong>The increasing incidence of PMR in secondary health care was exceeded by the declining incidence in primary health care. Most late-onset GCA developed within the first year after PMR diagnosis. Many patients continued treatment with PDN for 5 to 10 years, indicating a need for earlier use of concomitant therapies.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965742","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Longitudinal Changes in Cardiac Function Following Autologous Stem Cell Transplantation in Diffuse Systemic Sclerosis.","authors":"Jingjing He, Steele C Butcher, Xu Wang, Saad Ahmed, Jeroen J Bax, Jeska K de Vries-Bouwstra, Nina Ajmone Marsan","doi":"10.1002/art.70338","DOIUrl":"10.1002/art.70338","url":null,"abstract":"<p><strong>Objective: </strong>Cardiovascular involvement is frequent in patients with systemic sclerosis (SSc). Autologous stem cell transplantation (ASCT) has emerged as a disease-modifying therapy for diffuse SSc, but its long-term impact on cardiac function remains unclear. We aim to examine the changes in left ventricular (LV) function after ASCT and their potential prognostic significance.</p><p><strong>Methods: </strong>From the Leiden Systemic Sclerosis cohort, 43 patients with diffuse SSc who underwent ASCT were matched 1:1 with controls with SSc based on sex, age, and disease duration. Patients with overt cardiac or pulmonary involvement were excluded. Serial echocardiography was performed annually, including LV ejection fraction (LVEF), global longitudinal strain (GLS), and diastolic parameters.</p><p><strong>Results: </strong>Among the included patients, mean age was 44.1 ± 10.5 years; 52.3% were female. At baseline, patients with ASCT showed mildly reduced LVEF (52.5% ± 9.1% vs 56.1% ± 6.3%, P = 0.044) and LV GLS (18.0% ± 2.6% vs 19.5% ± 2.5%, P = 0.014) compared to controls. During follow-up, ASCT was associated with significant improvement in LVEF (adjusted β = 1.59%/y, P < 0.001) and GLS (adjusted β = 0.71%/y, P < 0.001), whereas controls showed progressive decline. Diastolic parameters remained stable over time in both groups. Time-dependent changes in LV GLS, but not LVEF, were independently associated with all-cause mortality (adjusted hazard ratio 0.73 per %, 95% confidence interval 0.61-0.86, P = 0.0002).</p><p><strong>Conclusion: </strong>In patients with diffuse SSc, ASCT is associated with significant improvements in cardiac systolic function over time without adverse effects on diastolic function. These findings support the cardiac safety of ASCT, suggest potential cardiovascular benefit beyond systemic disease control, and highlight the importance of longitudinal monitoring with advanced echocardiography in SSc.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965793","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Images: Nasal-type extranodal natural killer/T cell lymphoma mimicking antineutrophil cytoplasmic antibody-associated vasculitis.","authors":"Hakeem Asad, Kenneth J Warrington","doi":"10.1002/art.70334","DOIUrl":"10.1002/art.70334","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962702","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Expert Perspectives: Toward Treat-to-Target Management in Adult Idiopathic Inflammatory Myopathies.","authors":"Shiri Keret, Nantakarn Pongtarakulpanit, Rohit Aggarwal","doi":"10.1002/art.70335","DOIUrl":"10.1002/art.70335","url":null,"abstract":"<p><p>Treat-to-target has transformed the management of several rheumatic diseases through predefined therapeutic goals, structured disease assessment, and timely treatment adjustment. Despite major advances in the understanding and treatment of idiopathic inflammatory myopathies (IIM), a formal treat-to-target framework for adult IIM has not yet been established. Given the substantial burden of persistent disease activity, treatment-related toxicity, and irreversible organ damage, together with recent advances in IIM therapeutics, there is increasing rationale for adopting a structured, target-oriented approach in these disorders. In this expert perspective, we discuss the principles of treat-to-target in adult IIM and review the evidence supporting its application. We examine key challenges that limit implementation, including the absence of validated definitions for remission and low disease activity, limitations of existing disease activity measures, the heterogeneity of clinical manifestations across organ systems, and the difficulty of distinguishing active inflammation from irreversible damage. We further discuss the role of skin, pulmonary, and patient-reported outcome assessments within a domain-based monitoring framework, together with practical considerations regarding biomarker interpretation and individualized treatment targets. Drawing on experience from other systemic autoimmune rheumatic diseases, we propose a pragmatic framework for treat-to-target implementation in adult IIM. This approach emphasizes measurable treatment goals, structured multidimensional assessment, shared decision-making, and adaptation of targets according to disease phenotype, organ involvement, and accumulated damage. Although important knowledge gaps remain, particularly regarding disease state definitions and outcome measure standardization, a treat-to-target strategy may improve disease control, reduce long-term morbidity, and provide a framework for clinical care and research in IIM.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148962723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Dual Interleukin-17A and Interleukin-17F Inhibition With Bimekizumab on Inflammatory and Structural Lesions in Axial Spondyloarthritis: Magnetic Resonance Imaging and Radiographic Outcomes From Two Phase 3 Studies and Their Open-Label Extension.","authors":"Walter P Maksymowych, Sofia Ramiro, Denis Poddubnyy, Xenofon Baraliakos, Robert G W Lambert, Ute Massow, Tom Vaux, Chetan Prajapati, Alexander Marten, Natasha de Peyrecave, Mikkel Østergaard","doi":"10.1002/art.70336","DOIUrl":"10.1002/art.70336","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the impact of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, on sacroiliac joints (SIJ) and spine inflammation/structural damage in axSpA using magnetic resonance imaging (MRI) scans/radiographs from the phase 3 studies BE MOBILE 1 (non-radiographic axSpA [nr-axSpA]) and 2 (radiographic axSpA [r-axSpA]) and their open-label extension (OLE).</p><p><strong>Methods: </strong>BE MOBILE 1 and 2 comprised 16-week double-blind placebo-controlled and 36-week maintenance periods. From week 16, all received subcutaneous bimekizumab 160 mg every 4 weeks. At week 52, patients could enter the OLE to continue bimekizumab. MRI scans were evaluated by treatment arm at baseline and weeks 16 and 52 in BE MOBILE 1 and 2 MRI substudies using Spondyloarthritis Research Consortium of Canada (SPARCC) SIJ and Berlin spine inflammation scores, and SPARCC SIJ structural score (SSS; erosion, backfill, fat lesions, and ankylosis). In patients with baseline and week 104 radiographs, structural damage was assessed in the SIJ (modified New York [mNY] criteria; nr-axSpA) and spine (modified Stoke Ankylosing Spondylitis Spinal Score [mSASSS]; r-axSpA). Observed case data are reported.</p><p><strong>Results: </strong>At week 52, bimekizumab-randomized patients had substantially reduced inflammation (mean change from baseline [CfB]: SPARCC SIJ, nr-axSpA -7.6; r-axSpA -5.1; Berlin spine, nr-axSpA -0.5; r-axSpA -2.5), decreased erosion scores (nr-axSpA -1.8; r-axSpA -1.8), increased backfill (nr-axSpA 0.9; r-axSpA 0.6) and fat lesion scores (nr-axSpA 0.7; r-axSpA 0.5), and minimal changes in ankylosis (nr-axSpA 0.0; r-axSpA 0.2). With bimekizumab treatment to week 104, radiographs showed mean CfB of 0.03 in mNY (nr-axSpA) and mSASSS of 0.3 (r-axSpA).</p><p><strong>Conclusion: </strong>Dual inhibition of IL-17A and IL-17F with bimekizumab led to substantial reductions in MRI SIJ/spine inflammation, gradual decreases in SIJ erosion, and minimal radiographic progression in the SIJ/spine in patients with axSpA.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148965767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}